Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jul 18;39(7):BSR20190954.
doi: 10.1042/BSR20190954. Print 2019 Jul 31.

Association between PTEN and clinical-pathological features of osteosarcoma

Jian Zhou  1   2 , Xia Xiao  3   4 , Wanchun Wang  1 , Yingquan Luo  5
Affiliations
Meta-Analysis

Association between PTEN and clinical-pathological features of osteosarcoma

Jian Zhou et al. Biosci Rep. .

Abstract

Previous studies indicated the prognostic value of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in osteosarcoma (OS). There was a great degree of inconsistency between these reports. The aim of this meta-analysis was to investigate the clinicopathological features and prognostic role of PTEN positive expression on OS. We searched NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane library, China National Knowledge Internet database (CNKI), Wanfang database, Chinese VIP database and Chinese Biological Medical Database (CBM) for relevant papers published before 28 November 2018. The eligibility of all retrieved studies assessing the relationship between PTEN expression and clinicopathological and prognostic outcomes in OS were incorporated. Pooled odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the outcomes. A total of 13 studies with 580 OS patients were involved to assess the relationship between PTEN expression and clinicopathological features of OS. PTEN positive expression was significantly associated with male (OR = 1.57, 95% CI: 1.03-2.38, P=0.035<0.05) and OS high differentiation (OR = 2.33, 95% CI: 1.26-4.29, P=0.007<0.05). Additionally, positive expressions of PTEN predict no neoplasm metastasis (OR = 5.69, 95% CI: 3.64-8.90, P<0.05). The results of our study showed that positive expression of PTEN may predict higher 5-year survival in OS with the pooled OR of 8.73 (95% CI: 4.18-18.24, P<0.05). The results from the present study suggest that positive expression of PTEN is significantly associated with male, high differentiation, no metastasis and high 5-year overall survival rate in OS.

Keywords: Bone tumor.; Clinicopathological features; Meta-analysis; Osteosarcoma; PTEN; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. The flow diagram of literature screening
Figure 2
Figure 2. Forest plot showing the association between PTEN expression and OS
(A) Gender, (B) pathological classification, (C) metastasis, (D) age, (E) differentiation, (F) overall survival.
Figure 3
Figure 3. Sensitivity analysis on the association of PTEN expression in OS patients
(A) Gender, (B) pathological classification, (C) metastasis, (D) age, (E) differentiation, (F) overall survival.
Figure 4
Figure 4. Funnel plot in the meta-analysis of association of PTEN expression in OS patients
(A) Gender, (B) pathological classification, (C) metastasis, (D) age, (E) differentiation, (F) overall survival.
See this image and copyright information in PMC

References

    1. Bertucci F., Araujo J. and Giovannini M. (2013) Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand. J. Gastroenterol. 48, 4–810.3109/00365521.2012.711852 - DOI - PubMed
    1. Kong C. and Hansen M.F. (2009) Biomarkers in osteosarcoma. Expert Opin. Med. Diagn. 3, 13–2310.1517/17530050802608496 - DOI - PMC - PubMed
    1. Ottaviani G. and Jaffe N. (2009) The etiology of osteosarcoma. Cancer Treat. Res. 152, 15–3210.1007/978-1-4419-0284-9_2 - DOI - PubMed
    1. Morrow J.J. and Khanna C. (2015) Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. Crit. Rev. Oncog. 20, 173–19710.1615/CritRevOncog.2015013713 - DOI - PMC - PubMed
    1. Moriarity B.S., Otto G.M., Rahrmann E.P., Rathe S.K., Wolf N.K., Weg M.T.. et al. (2015) A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat. Genet. 47, 615–62410.1038/ng.3293 - DOI - PMC - PubMed

Publication types

MeSH terms